SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

Home・Lista de Ações・Ipsen SA.

Ipsen SA.

Abrir

SetorFinanças

155.6 2.64

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

151.4

Máximo

154.9

Indicadores-chave
By Trading Economics
Rendimento	-225M 110M
Vendas	36M 1.9B
P/E Médio do Setor	28.534 41.721
Rendimento de Dividendos	0.89
Margem de lucro	5.899
Funcionários	5,535
EBITDA	-171M 466M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	-5.58% downside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	0.89% 4.65%
Próximos Ganhos	30 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1.1B 13B
Abertura anterior	152.96
Fecho anterior	155.6

Sentimento de Notícias

By Acuity

42%

58%

120 / 439 Ranking em Finance

Ipsen SA. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de jun. de 2026, 21:51 UTC

Grandes Movimentos do Mercado

Merlin Shares Rally After Defense Department's Design Review Wraps

4 de jun. de 2026, 23:46 UTC

Conversa de Mercado

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 de jun. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 de jun. de 2026, 23:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 de jun. de 2026, 23:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Energy Resources of Australia to Enter Trading Halt

4 de jun. de 2026, 23:34 UTC

Conversa de Mercado

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

4 de jun. de 2026, 23:08 UTC

Conversa de Mercado

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 de jun. de 2026, 22:41 UTC

Conversa de Mercado

Australia Shares Set to Rise at the Open -- Market Talk

4 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

4 de jun. de 2026, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 de jun. de 2026, 20:16 UTC

Conversa de Mercado

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 de jun. de 2026, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 de jun. de 2026, 19:46 UTC

Conversa de Mercado

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 de jun. de 2026, 19:38 UTC

Conversa de Mercado

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 de jun. de 2026, 19:30 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 de jun. de 2026, 18:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 de jun. de 2026, 18:38 UTC

Ganhos

Money Quote: Tech Weakness in Context -- WSJ

4 de jun. de 2026, 18:24 UTC

Ganhos

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 de jun. de 2026, 17:09 UTC

Conversa de Mercado

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 de jun. de 2026, 16:58 UTC

Ganhos

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 de jun. de 2026, 16:46 UTC

Conversa de Mercado

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 de jun. de 2026, 16:38 UTC

Ganhos

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

4 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

4 de jun. de 2026, 16:13 UTC

Conversa de Mercado

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 de jun. de 2026, 16:11 UTC

Conversa de Mercado

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 de jun. de 2026, 15:56 UTC

Conversa de Mercado

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparação entre Pares

Variação de preço

Ipsen SA. Previsão

Preço-alvo

By TipRanks

-5.58% parte inferior

Previsão para 12 meses

Média 143.8 EUR -5.58%

Máximo 170 EUR

Mínimo 117 EUR

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Ipsen SA. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Ipsen SA. - Dist nos últimos 3 meses.

Sentimento

By Acuity

120 / 439 Ranking em Finanças

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.